See more : Banzai International, Inc. (BNZIW) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- NTG Clarity Networks Inc. (NYWKF) Income Statement Analysis – Financial Results
- PT Lippo General Insurance Tbk (LPGI.JK) Income Statement Analysis – Financial Results
- Cen Link Co., Ltd. (5254.TWO) Income Statement Analysis – Financial Results
- Maple Gold Mines Ltd. (MGM.V) Income Statement Analysis – Financial Results
- TUGA Innovations, Inc. (TUGA.CN) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences banks strong 3Q on increasing sales of its flagship VINIA product in Israel and the US
BioHarvest Sciences Inc. reported that it banked a strong third quarter, fueled by increasing demand for its flagship VINIA product in Israel and the US. The company said VINIA 3Q sales revenues were US$688,000, representing a 44% jump from 2Q and...
BioHarvest Sciences closes second and final tranche of private placement
BioHarvest Sciences Inc said it has closed its second and final tranche of the private placement which was previously announced on August 4, 2021. The private placement saw the company issue a total of 7,781,375 units for proceeds of C$3,501,619...
BioHarvest Sciences says new manufacturing facility in Israel has successfully met certification requirements ahead of time
BioHarvest Sciences Inc. has announced that the new manufacturing facility in Israel has successfully met the Israeli Ministry of Health's ISO9001 and ISO22000 (HACCP) certification requirements ahead of time. The company noted that the ISO9001 certification covers internationally recognized standards for...
BioHarvest Sciences says it has successfully scaled its cannabis cells with trichomes production by a factor of 250 times and it is now growing them in medium-scale bioreactors
BioHarvest Sciences Inc. said it has successfully scaled its Cannabis cells with trichomes production by a factor of 250 times and it is now growing cannabis in medium-scale bioreactors, paving the way for its next scale-up milestone, where it will reach...
BioHarvest Sciences closes first tranche of previously announced non-brokered private placement for gross proceeds of around C$3.080M
BioHarvest Sciences Inc. said it has closed the first tranche of its non-brokered private placement previously announced on August 4, 2021, for gross proceeds of C$3,080,415.60.
BioHarvest Sciences unveils groundbreaking cannabis trichome structure
BioHarvest Sciences Inc has unveiled a new, groundbreaking "Amalgamated Trichomes Coral Structure" (ATCS) that the company says will revolutionize the production of cannabis. The company has successfully grown multiple trichomes in coral-shaped clusters where they are attached together in a natural...
BioHarvest Sciences launches private placement of up to 8,888,889 units to raise gross proceeds of up to C$4 million
BioHarvest Sciences Inc. said its board of directors has approved a private placement of up to 8,888,889 units at a price of C$0.45 per unit to raise gross proceeds of up to C$4 million.
BioHarvest Sciences appoints two top-ranked law firms to pursue regulatory approvals of its cannabis and hemp products in US and Canada
BioHarvest Sciences Inc. said it has appointed top-ranked law firms DLA Piper and GOWLING WLG to assist it in fulfilling all required compliance mandates and regulatory approvals to produce and commercialize cannabis and hemp products in the US and Canada.
BioHarvest Sciences announces publication of its inaugural Environmental, Social, and Governance report
BioHarvest Sciences Inc (CSE:BHSC) (OTCMKTS:CNVCF) (FRA:8MV) has announced the publication of its inaugural Environmental, Social, and Governance (ESG) report, detailing the company's performance and ongoing commitment to creating a sustainable future. BioHarvest said it is the first biotechnology company engaged...
BioHarvest Sciences reports record 2Q sales orders in Israel
BioHarvest Sciences Inc (CSE:BHSC) has reported record second-quarter sales orders in Israel. For the period ended June 30, 2021, the company said sales orders reached US$409,272, compared to US$371,944 in the 1Q of 2021 and US$44,600 in the 2Q of 2020.
Source: https://incomestatements.info
Category: Stock Reports